187 related articles for article (PubMed ID: 20564104)
1. Epigenetic and genetic silencing of CHFR in esophageal adenocarcinomas.
Soutto M; Peng D; Razvi M; Ruemmele P; Hartmann A; Roessner A; Schneider-Stock R; El-Rifai W
Cancer; 2010 Sep; 116(17):4033-42. PubMed ID: 20564104
[TBL] [Abstract][Full Text] [Related]
2. Aberrant promoter hypermethylation of the CHFR gene in oral squamous cell carcinomas.
Baba S; Hara A; Kato K; Long NK; Hatano Y; Kimura M; Okano Y; Yamada Y; Shibata T
Oncol Rep; 2009 Nov; 22(5):1173-9. PubMed ID: 19787237
[TBL] [Abstract][Full Text] [Related]
3. Promoter methylation of p16, Runx3, DAPK and CHFR genes is frequent in gastric carcinoma.
Hu SL; Kong XY; Cheng ZD; Sun YB; Shen G; Xu WP; Wu L; Xu XC; Jiang XD; Huang DB
Tumori; 2010; 96(5):726-33. PubMed ID: 21302620
[TBL] [Abstract][Full Text] [Related]
4. Mechanism and pathobiologic implications of CHFR promoter methylation in gastric carcinoma.
Gao YJ; Xin Y; Zhang JJ; Zhou J
World J Gastroenterol; 2008 Aug; 14(32):5000-7. PubMed ID: 18763281
[TBL] [Abstract][Full Text] [Related]
5. CHFR promoter hypermethylation and reduced CHFR mRNA expression in ovarian cancer.
Gao Y; Lou G; Zhang GM; Sun XW; Ma YY; Yang YM; Liu G
Int J Biol Markers; 2009; 24(2):83-9. PubMed ID: 19634111
[TBL] [Abstract][Full Text] [Related]
6. CHFR aberrant methylation involves a subset of human lung adenocarcinoma associated with poor clinical outcomes.
Koga T; Takeshita M; Ijichi K; Yano T; Maehara Y; Sueishi K
Hum Pathol; 2013 Jul; 44(7):1382-90. PubMed ID: 23415374
[TBL] [Abstract][Full Text] [Related]
7. Chfr expression is downregulated by CpG island hypermethylation in esophageal cancer.
Shibata Y; Haruki N; Kuwabara Y; Ishiguro H; Shinoda N; Sato A; Kimura M; Koyama H; Toyama T; Nishiwaki T; Kudo J; Terashita Y; Konishi S; Sugiura H; Fujii Y
Carcinogenesis; 2002 Oct; 23(10):1695-9. PubMed ID: 12376479
[TBL] [Abstract][Full Text] [Related]
8. Promoter hypermethylation of the Chfr gene in neoplastic and non-neoplastic gastric epithelia.
Honda T; Tamura G; Waki T; Kawata S; Nishizuka S; Motoyama T
Br J Cancer; 2004 May; 90(10):2013-6. PubMed ID: 15138487
[TBL] [Abstract][Full Text] [Related]
9. A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype.
Baretti M; Karunasena E; Zahurak M; Walker R; Zhao Y; Pisanic TR; Wang TH; Greten TF; Duffy AG; Gootjes E; Meijer G; Verheul HMW; Ahuja N; Herman JG; Azad NS
Clin Transl Sci; 2021 May; 14(3):954-963. PubMed ID: 33811727
[TBL] [Abstract][Full Text] [Related]
10. Promoter methylation of CHFR gene in gastric carcinoma tissues detected using two methods.
Cheng ZD; Hu SL; Sun YB; Xu WP; Shen G; Kong XY
Chin J Cancer; 2010 Feb; 29(2):163-6. PubMed ID: 20109344
[TBL] [Abstract][Full Text] [Related]
11. [Aberrant promoter hypermethylation of CHFR in nasopharyngeal carcinoma].
Huang T; Du C; Yu N; Xiao X; Zhou X; Wang S; Huang G; Zhang Z
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2011 Aug; 25(16):746-50. PubMed ID: 22070084
[TBL] [Abstract][Full Text] [Related]
12. CHFR: a key checkpoint component implicated in a wide range of cancers.
Sanbhnani S; Yeong FM
Cell Mol Life Sci; 2012 May; 69(10):1669-87. PubMed ID: 22159584
[TBL] [Abstract][Full Text] [Related]
13. Pathobiologic implications of methylation and expression status of Runx3 and CHFR genes in gastric cancer.
Hu SL; Huang DB; Sun YB; Wu L; Xu WP; Yin S; Chen J; Jiang XD; Shen G
Med Oncol; 2011 Jun; 28(2):447-54. PubMed ID: 20300977
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes.
Banno K; Yanokura M; Kawaguchi M; Kuwabara Y; Akiyoshi J; Kobayashi Y; Iwata T; Hirasawa A; Fujii T; Susumu N; Tsukazaki K; Aoki D
Int J Oncol; 2007 Oct; 31(4):713-20. PubMed ID: 17786301
[TBL] [Abstract][Full Text] [Related]
15. Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.
Li Z; Zhang H; Yang J; Hao T; Li S
Cell Biol Int; 2012 May; 36(5):427-32. PubMed ID: 21864295
[TBL] [Abstract][Full Text] [Related]
16. CHFR suppression by hypermethylation sensitizes endometrial cancer cells to paclitaxel.
Wang X; Yang Y; Xu C; Xiao L; Shen H; Zhang X; Li T; Li X
Int J Gynecol Cancer; 2011 Aug; 21(6):996-1003. PubMed ID: 21792009
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint with forkhead-associated and ring finger promoter hypermethylation correlates with microsatellite instability in gastric cancer.
Oki E; Zhao Y; Yoshida R; Masuda T; Ando K; Sugiyama M; Tokunaga E; Morita M; Kakeji Y; Maehara Y
World J Gastroenterol; 2009 May; 15(20):2520-5. PubMed ID: 19469003
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic inactivation of CHFR in nasopharyngeal carcinoma through promoter methylation.
Cheung HW; Ching YP; Nicholls JM; Ling MT; Wong YC; Hui N; Cheung A; Tsao SW; Wang Q; Yeun PW; Lo KW; Jin DY; Wang X
Mol Carcinog; 2005 Aug; 43(4):237-45. PubMed ID: 15937956
[TBL] [Abstract][Full Text] [Related]
19. The anti-proliferative effects of the CHFR depend on the forkhead associated domain, but not E3 ligase activity mediated by ring finger domain.
Fukuda T; Kondo Y; Nakagama H
PLoS One; 2008 Mar; 3(3):e1776. PubMed ID: 18335050
[TBL] [Abstract][Full Text] [Related]
20. Promoter hypermethylation and silencing of CHFR mitotic stress checkpoint gene in human gastric cancers.
Kang HC; Kim IJ; Park JH; Shin Y; Park HW; Ku JL; Yang HK; Lee KU; Choe KJ; Park JG
Oncol Rep; 2004 Jul; 12(1):129-33. PubMed ID: 15201973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
